Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
about
FES kinases are required for oncogenic FLT3 signalingmTOR inhibitors in advanced renal cell carcinomaTargeting mTOR for the treatment of AML. New agents and new directionsThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyArsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerWill targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapyPI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cellsInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerThe Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesAutocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibodyTargeting the translational machinery as a novel treatment strategy for hematologic malignanciesRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Recent advances in the discovery of small molecule mTOR inhibitors.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachThe phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemiaDefining the pathway to insulin-like growth factor system targeting in cancer.A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic interventionRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemiaUpregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1RNRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemiaAutomatic context-specific subnetwork discovery from large interaction networksDual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical modelTherapeutic destruction of insulin receptor substrates for cancer treatment.Rational Combinations of Targeted Agents in AML
P2860
Q24297863-47282196-B0B6-4FCC-8330-7A360606D270Q24612127-75649AFC-12EF-4550-93D8-3116817AD803Q24617223-AC5B8572-25D6-4EB7-BF30-1534814F8BB1Q26799596-DEC53172-AF64-4D3A-A9BF-096CBAB0C583Q27332151-56C65BE7-E896-497F-BFE0-A6ECDE391C96Q28078957-C7F9CFDE-008B-4E07-A520-741B5143B2ADQ28299026-BEAB2603-E0F6-4D0D-A406-D594520F3E75Q28484680-ACEC948F-318B-47B1-B8DD-12BFB9762425Q29618030-A1412FDE-AC5B-43A0-872E-FEBBA4A40ACBQ30277177-3828F5AB-1E61-4399-8C97-052886F9D0ECQ33418329-9F66B573-B904-4725-99AE-0C07A0D84BC5Q33437313-A065C010-867D-4AF8-AB5F-40CA63ABC77AQ33493174-460F624E-1121-4449-B21B-DA33A99BAEF3Q33558141-9225B9A1-89B2-469E-9054-BA8E0C4D5018Q33707416-366F9EA5-D029-40F3-8D4C-CE1065DC9862Q33747291-C655D35F-7E8D-43D6-95DD-FCD1C6257A4BQ33840360-1243A91E-07EE-4D5D-B96F-5A704FEEE66FQ33852446-9A6E9DCD-99D2-4794-9072-7C008C5E2912Q33925323-3F9123B5-5E28-45EF-8060-D7DC868CF417Q34024558-5FA8ECE3-389D-4358-B7ED-CFC0F92F54FCQ34049613-4DEAA739-2BB6-490E-9AC8-BE6A64CEE70CQ34080843-B4F1608A-C8D8-4476-AEBF-927CECAB9D8FQ34107722-89FFEBC7-24E6-40E6-8940-82B6E43817E3Q34140027-E50168FB-B872-4017-85F0-EFEF2C7087B6Q34164683-D5D92D2C-1E71-4FB7-A711-88522326D8A3Q34173253-CBD93821-B5E2-44D7-BD83-D573EBCC20E8Q34260622-72592E63-3AE2-4A9B-A9D8-D3BF6E06FB4AQ34286759-B81F31A0-2B98-44C3-B723-170890FAD113Q34307356-0C3DF904-6769-4753-A638-0E1FE56EC6AAQ34329614-7500EA6A-CA6E-4D62-9E85-75359A2F3331Q34360637-3A2F523D-5D38-4534-96DF-E98338BFEDCDQ34417518-2C6E34A9-D808-43E8-A265-61D1545F72C5Q34428550-1B4505E8-6ABB-4D4C-982B-AF9A420A3730Q34438500-8F72E433-ED59-4892-927C-B138733BA2AEQ34551220-79389A9C-5690-457A-8549-4049BDF20547Q35083330-C15ADD8C-C2F2-40CC-B083-439ACDE698CCQ35091507-FBDD6556-F6CD-442E-8695-7C8C3201E2BCQ35176311-62D4430E-5FDB-4604-9E2E-20F1E2A1FB62Q35343877-626A1C74-3F85-42EB-BEB5-10427B03B61CQ35750491-C4635F85-3767-4F8D-9C8F-9DCD301CA3FC
P2860
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Mammalian target of rapamycin ...... c inhibition of both pathways.
@en
type
label
Mammalian target of rapamycin ...... c inhibition of both pathways.
@en
prefLabel
Mammalian target of rapamycin ...... c inhibition of both pathways.
@en
P2093
P50
P1433
P1476
Mammalian target of rapamycin ...... ic inhibition of both pathways
@en
P2093
Catherine Lacombe
François Dreyfus
Patrick Mayeux
Pierre Sujobert
Sophie Park
P304
P356
10.1182/BLOOD-2007-03-080796
P407
P577
2007-09-18T00:00:00Z